Noile-Immune Biotech Inc
TSE:4893
Noile-Immune Biotech Inc
Research & Development
Noile-Immune Biotech Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
N
|
Noile-Immune Biotech Inc
TSE:4893
|
Research & Development
-ÂĄ646.7m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GNI Group Ltd
TSE:2160
|
Research & Development
-ÂĄ2.7B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
||
PeptiDream Inc
TSE:4587
|
Research & Development
-ÂĄ3.2B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Takara Bio Inc
TSE:4974
|
Research & Development
-ÂĄ7.6B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-10%
|
||
Pharma Foods International Co Ltd
TSE:2929
|
Research & Development
-ÂĄ1B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-18%
|
||
C
|
Cuorips Inc
TSE:4894
|
Research & Development
-ÂĄ209.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Noile-Immune Biotech Inc
Glance View
Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.
See Also
What is Noile-Immune Biotech Inc's Research & Development?
Research & Development
-646.7m
JPY
Based on the financial report for Dec 31, 2023, Noile-Immune Biotech Inc's Research & Development amounts to -646.7m JPY.
What is Noile-Immune Biotech Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-17%
Over the last year, the Research & Development growth was -93%. The average annual Research & Development growth rates for Noile-Immune Biotech Inc have been -17% over the past three years .